GlassScriptPhysician profile
Neely Elisha
NPI 1508293978
$13,460.34
in general payments reported to CMS, 2019-2025
24 companies · $401 in 2025
The $401 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.57 · 2020: $47.18 · 2021: $136 · 2022: $6,342 · 2023: $6,266 · 2024: $205 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $871.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,045.59 | 2022-2025 | Davinci Xi |
| Abbvie INC. | $210.64 | 2021-2023 | |
| Evofem Biosciences, INC. | $201.30 | 2021-2024 | Phexxi |
| Astellas Pharma US INC | $126.99 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $93.29 | 2020-2025 | Aptima, Acessa Provu System, Fluent Fluid Management System |
| Organon LLC | $91.30 | 2022-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $72.64 | 2021-2024 | |
| Boston Scientific Corporation | $68.51 | 2019-2025 | General - Pain Management |
| Davol INC. | $68.11 | 2025 | Arista |
| Sage Therapeutics, LLC | $67.00 | 2025 | Zurzuvae |
| Baxter Healthcare | $60.77 | 2024 | Perclot |
| Exact Sciences Corporation | $60.15 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $46.85 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $45.08 | 2022-2023 | Injectafer |
| Exeltis, USA INC. | $43.95 | 2020-2025 | Slynd |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $43.90 | 2025 | |
| Supernus Pharmaceuticals, INC. | $15.66 | 2025 | Qelbree |
| Agile Therapeutics, INC. | $15.43 | 2022 | |
| Glaxosmithkline, LLC. | $14.91 | 2020 | |
| Pfizer INC. | $14.71 | 2024 | |
| Millicent US INC | $14.20 | 2025 | Femlyv, Intrarosa |
| Novo Nordisk INC | $13.99 | 2023 | Wegovy |
| Pacira Pharmaceuticals Incorporated | $12.72 | 2022 | |
| Therapeuticsmd, INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neely Elisha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.